The Association of Gene Polymorphisms With Invasive Bacterial Infections in Neonates and Young Infants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-04-25

Study Completion Date

2024-03-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Invasive bacterial infections (IBIs) are globally significant, with high mortality rates, particularly within the critical 0-3 month age bracket. The first three months of life mark a peak in IBI prevalence, with an estimated 10-20% of febrile presentations in this age group resulting in an IBI diagnosis. Although multiple factors are implicated in this heightened vulnerability, the precise mechanisms driving the differential development of IBIs among similarly situated infants remain unclear. Genetic diversity and susceptibility are increasingly recognized as influential factors. Extensive literature demonstrates a correlation between genetic polymorphisms and susceptibility to invasive bacterial infections.

This study aims to explore the association of gene polymorphisms TLR4 rs2149356 (c.261-468T\>G), LTA rs2229094 (c.37T\>C), and RFP175 rs1585110 (c.246+8853G\>A) with the occurrence of invasive bacterial infections in the population of children aged under 3 months.

We conducted a prospective observational study at a leading tertiary care hospital. The cohort included 100 infants aged 0-3 months diagnosed with IBIs alongside 100 control infants presenting for non-infectious conditions such as trauma, infantile colic, and hyperbilirubinemia. Cases with any symptoms suggesting an infection were excluded from the control group. Invasive bacterial infections categorized in this study included meningitis, pneumonia, sepsis, bacteremia, urinary tract infections, and invasive bacterial gastroenteritis. Diagnostic criteria were stringent: meningitis was confirmed via signs of bacterial infection in cerebrospinal fluid; pneumonia through auscultatory findings and radiographic evidence of pulmonary infiltrates; bacteremia by positive blood cultures; urinary tract infections by significant bacterial cultures from sterile catheterization; and gastroenteritis by the identification of pathogenic organisms in stool cultures. No additional blood was taken from the patients for the study. Instead, blood samples that were collected for tests determined by the physicians due to the patients' condition in the emergency department were retrieved from the laboratory after the requested tests were completed and reused for the study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Invasive Group A Streptococcal Infection

NCT05788861

Sepsis Due to Streptococcus, Group A Risk Factors Severe Infection +6 more

RECRUITING

Infant Immune Response to Bacterial Infection

NCT00546195

Prematurity Histologic Chorioamnionitis

COMPLETED

Invasive Group A Streptococcus (GAS) Infection in Children: Bacterial Virulence Factors and Detection of Host Immunological and/or Genetic Factors of Predisposition to Infections

NCT02010294

Invasive GAS Infection

COMPLETED

Genetic Susceptibility to Severe Streptococcal Infections

NCT01911572

Invasive Streptococcal Infection Invasive Group A Streptococcal Disease Invasive Group B Streptococcal Disease +1 more

UNKNOWN

Immune Response to BCG Vaccination in Neonates Born to HIV and LTBI Infected and Non-infected Mothers

NCT03383211

HIV Infections Neonatal Infection LTBI - Latent Tuberculosis Infection +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We conducted a prospective observational study at a leading tertiary care hospital in Turkey. The cohort included 100 infants aged 0-3 months diagnosed with IBIs alongside 100 control infants presenting for non-infectious conditions. Ethical approval was secured from the institutional review board in compliance with the Declaration of Helsinki. Informed consent was obtained in written form from the parents or legal guardians of all participants prior to enrollment.

Invasive bacterial infections categorized in this study included meningitis, pneumonia, sepsis, bacteremia, urinary tract infections, and invasive bacterial gastroenteritis. Diagnostic criteria were stringent: meningitis was confirmed via signs of bacterial infection in cerebrospinal fluid; pneumonia through auscultatory findings and radiographic evidence of pulmonary infiltrates; bacteremia by positive blood cultures; urinary tract infections by significant bacterial cultures from sterile catheterization; and gastroenteritis by the identification of pathogenic organisms in stool cultures.

DNA was extracted from whole blood samples using the QIAamp DNA Mini Kit (Qiagen), according to the manufacturer's instructions. The purity and concentration of the DNA were quantified using a NanoDrop ND-1000 Spectrophotometer. Only DNA samples that met the quality and concentration criteria proceeded to sequencing. The sequence analysis targeted specific regions pertinent to the polymorphisms identified in the study's objectives.

DNA samples were processed using a sequence of analytical techniques to identify the polymorphisms TLR4 rs2149356 (c.261-468T\>G), LTA rs2229094 (c.37T\>C), and RFP175 rs1585110 (c.246+8853G\>A), as detailed in our previous work \[18\]:

Primers targeting the regions encompassing TLR4 rs2149356 (c.261-468T\>G), LTA rs2229094 (c.37T\>C), and RFP175 rs1585110 (c.246+8853G\>A) were designed using the Primer3 web tool. Criteria for primer design included a length of 18-24 base pairs, GC content between 30-50%, specificity to the target DNA region, and a melting temperature (Tm) ranging from 58-62 °C to ensure optimal amplification of a 300-500 base pair region.

Polymerase Chain Reaction (PCR) was employed for the amplification of the target regions. Each reaction mixture, prepared in a 25 µl volume, contained 0.4 µM of each primer, 2 ng of genomic DNA, 4 mM MgCl2, 0.05 µl Taq DNA polymerase, and 0.4 mM of each dNTP. Twelve such mixtures were assembled in PCR tubes. Amplification was performed under optimized conditions in a thermal cycler.

Post-amplification, the PCR products were subjected to agarose gel electrophoresis for verification. A 2% agarose gel was prepared by dissolving agarose in TBE buffer, followed by addition of ethidium bromide post-cooling. For electrophoresis, PCR products were mixed with loading dye and introduced into the gel alongside a DNA ladder. The electrophoresis was run at 120 volts, after which the gel was visualized under UV light using a gel documentation system.

After verification of the target amplicons by agarose gel electrophoresis, the PCR products were prepared for sequencing. The sequencing was performed using the Illumina MiSeq platform. This high-throughput sequencing process generated FastQ files, which were then assembled into BAM files for detailed examination. Sequence alignment and variant identification were conducted using the Integrative Genomics Viewer. Allelic variants within the sequences of the TLR4 rs2149356, LTA rs2229094, and RFP175 rs1585110 genes were meticulously identified and annotated for each subject in the study cohort.

Allelic and genotypic frequencies of the polymorphisms TLR4 rs2149356, LTA rs2229094, and RFP175 rs1585110 were assessed in patients with invasive bacterial infections compared to control subjects. Genotypic frequencies in the dominant model were evaluated by comparing the combined homozygous and heterozygous variants against the homozygous wild-type. Conversely, the recessive model analysis involved comparing homozygous variants to the combined heterozygous and homozygous wild-type genotypes.

Statistical computations were performed using IBM SPSS Statistics version 25. Categorical variables were analyzed using the chi-square test, and the association risks were quantified as odds ratios with 95% confidence intervals. A p-value of less than 0.05 was set as the threshold for statistical significance.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Polymorphism, Genetic Bacterial Infections Infant

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

gene polymorphisms

The cohort included 100 infants aged 0-3 months diagnosed with IBIs alongside 100 control infants presenting for non-infectious conditions.

Group Type OTHER

Specific single nucleotide polymorphisms

Intervention Type OTHER

Next-generation sequencing was performed to analyze the TLR4, LTA, and RFP175 genes, with a focus on specific single nucleotide polymorphisms

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Specific single nucleotide polymorphisms

Next-generation sequencing was performed to analyze the TLR4, LTA, and RFP175 genes, with a focus on specific single nucleotide polymorphisms

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Infants aged between 1 day and 90 days (under 3 months)
* Hospitalized for evaluation of suspected invasive bacterial infections
* Informed consent obtained from parent(s) or legal guardian(s)
* Blood, urine, cerebrospinal fluid (CSF), or stool samples collected within 72 hours of admission
* Genetic material (blood sample) available for DNA extraction

Exclusion Criteria

* Known or suspected congenital immunodeficiency
* Previous diagnosis of genetic syndromes affecting immune function
* Major congenital anomalies or chromosomal abnormalities
* Antibiotic therapy initiated more than 24 hours before sample collection
* Parental refusal to participate or withdraw consent

Minimum Eligible Age

1 Day

Maximum Eligible Age

3 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes